Table 1: Demographics of patients with systemic lupus erythematosus (SLE) ().

DemographicsLN SLENon-LN SLE

Patient number (%)58/134 (43.28)76/134 (56.72)NA
Age (mean ± SEM) (range, years)37.34 ± 1.55 (18–65)39.27 ± 1.59 (12–68)0.2359
Gender (male/female) (% female)6/52 (89.66)10/66 (86.84)NA
Disease duration (mean ± SD) (range, years)6.23 ± 0.56 (0.5–20)5.30 ± 0.79 (0.2–18)0.3768
SLEDAI score (range) 14.05 ± 0.97 (0–36)6.62 ± 0.52 (0–18)<0.0001
ACL Ab (+) number (%) 42/58 (72.41)48/76 (63.18)NA
Anti-C1q (+) number (%)49/58 (84.48)31/76 (40.79)NA
Anti-C1q (AU/mL)78.63 ± 16.87 26.88 ± 9.236<0.0001
Anti-dsDNA (+) number (%)58/58 (100)76/76 (100)NA
Anti-dsDNA (IU/mL)67.63 ± 11.70 48.33 ± 7.7210.1554
ANA (+) number (%)57/58 (98.28)73/76 (96.05)NA
ANA titer3038 ± 466.22499 ± 376.50.3553
Anti-Rib-P (+) number (%) 12/58 (20.69)12/76 (15.79)NA
Anti-Smith (Sm) (+) number (%)18/58 (31.03)15/76 (19.74)NA
Anti-SSA Ab (+) number (%)28/58 (48.28)27/76 (35.53)NA
Anti-SSB Ab (+) number (%)15/58 (25.86)10/76 (13.16)NA
pANCA (+) number (%)16/58 (27.59)17/76 (30.36)NA
cANCA (+) number (%)1/58 (1.72)0/76 (0.00)NA
C3 (µg/mL)0.5091 ± 0.0340 0.6680 ± 0.034850.0018
C4 (µg/mL)0.08557 ± 0.0082 0.1145 ± 0.01120.0508

Ab: antibody; ACL: anticardiolipin; ANA: antinuclear antibody; cANCA: cytoplasmic antineutrophil cytoplasmic antibody; LN: lupus nephritis; pANCA: perinuclear antineutrophil cytoplasmic antibody; Rib-P: ribosomal P-proteins; RNP: ribonucleoprotein; SSA: Sjogren’s syndrome A; SSB: anti-Sjogren’s syndrome B.
; and .